Sistema de Salut de Catalunya
Institut Català de la Salut
[Pellegrino B, Musolino A] Medical Oncology and Breast Unit, University Hospital of Parma, Parma, Italy. [Llop-Guevara A, Serra V] Experimental Therapeutics Group, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain. [De Silva P] Molecular Immunology Unit, Institut Jules Bordet and Universite Libre de Bruxelles, Bruxelles, Belgium. [Hlavata Z] Medical Oncology Department, CHR Mons-Hainaut, Mons, Belgium
Vall d'Hebron Barcelona Hospital Campus
2021-10-27T12:55:34Z
2021-10-27T12:55:34Z
2019
2020-02-01
Càncer de mama; Immunoteràpia; Danys en l’ADN
Cáncer de mama; Inmunoterapia; Daño en el ADN
Breast Cancer; Immunotherapy; DNA damage
The success of cancer immunotherapy with immune checkpoint blockade (ICB) has demonstrated the importance of targeting a preexisting immune response in a broad spectrum of tumors. This is particularly novel and relevant for less immunogenic tumors, such as breast cancer (BC), where the efficacy of ICB was more evident in the triple-negative (TNBC) subtype, in earlier stages, and in association with chemotherapy. Tumors harboring homologous recombination DNA repair (HRR) deficiency (HRD) are supposed to have a higher number of mutations, hence a higher tumor mutational burden, which could potentially make them more sensitive to immunotherapy. However, the mechanisms involved in ICB sensitivity and patient selection are still yet to be defined in BC: whether the innate system could play a role and how the adaptive immunity could be linked with HRR pathways are the two key points of debate that we will discuss in this article. The aim of this review was to close the loop between what was found in clinical trial results so far, go back to laboratory theory and preclinical results and point out what needs to be clarified from now on.
B.P. was supported by European Society of Medical Oncology ( ESMO) with the aid of a grant from Roche.
Article
Published version
English
ADN - Reparació; Mama - Càncer - Immunoteràpia; DISEASES::Neoplasms::Neoplasms by Site::Breast Neoplasms; Other subheadings::Other subheadings::/therapy; PHENOMENA AND PROCESSES::Chemical Phenomena::Biochemical Phenomena::DNA Repair::Recombinational DNA Repair; ENFERMEDADES::neoplasias::neoplasias por localización::neoplasias de la mama; Otros calificadores::Otros calificadores::/terapia; FENÓMENOS Y PROCESOS::fenómenos químicos::fenómenos bioquímicos::reparación del ADN::reparación del ADN por recombinación
Elsevier
Translational Oncology;13(2)
https://doi.org/10.1016/j.tranon.2019.10.010
Attribution-NonCommercial-NoDerivatives 4.0 International
http://creativecommons.org/licenses/by-nc-nd/4.0/
